EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2023
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Annual Results/Annual Results
Corporate News Bad Neustadt a. d. Saale | 28 March 2024
RHÖN-KLINIKUM AG looks back on successful financial year 2023
“In the past year as well, RHÖN-KLINIKUM AG demonstrated its financial efficiency and put in a solid performance. This is extremely positive given the highly fraught economic situation of hospitals in Germany. It confirms that we’re on the right path with our strategic orientation. We are especially grateful to our employees for their extraordinary commitment and to our patients for the trust they put in our medical, therapeutic and care expertise”, said Prof. Dr Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM.
RHÖN-KLINIKUM AG continues to steadfastly pursue its strategic goals. The hospitals will focus on their core activities, i.e. on inpatient treatment services, with the goal of being able to provide patients with cutting-edge medical care at all sites. Moreover, the Company is investing in the expansion of outpatient care so that it can offer patients alternatives to an inpatient hospital stay meeting a high quality of medical care without having to sacrifice the standards of a treatment at a hospital. The focus is also on efforts to further expand digitalisation and to optimise clinical and administrative processes. The healthcare group embraces its ecological obligations in addition to its medical, social and corporate responsibilities. RHÖN-KLINIKUM AG is looking to achieve CO2-greenhouse gas neutrality in Scope 1 and Scope 2 emissions by financial year 2040. To achieve that, the Company is investing in sustainable technologies and continuously optimising its processes at all sites to protect the environment. “We see the most significant challenge of supplying sustainable energy to our hospital sites. That is why we have been closely scrutinising both consumption and efficiency and have come up with a transformation concept showing energy conservation and utilisation potential. The measures derived from this are the roadmap for our environmental strategy”, Kaltenbach explained.
For the coming financial year we expect revenues of 1.6 billion euros within a range of +/- 5 per cent. This forecast reflects the further heightened regulatory interference by the German legislator. We point out that our outlook is further subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024.
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
28.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | RHÖN-KLINIKUM Aktiengesellschaft |
Salzburger Leite 1 | |
97616 Bad Neustadt a.d.Saale | |
Germany | |
Phone: | +49 (0)9771 - 65-0 |
Fax: | +49 (0)9771 - 97 467 |
E-mail: | rka@rhoen-klinikum-ag.com |
Internet: | www.rhoen-klinikum-ag.com |
ISIN: | DE0007042301 |
WKN: | 704230 |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1869377 |
End of News | EQS News Service |
|
1869377 28.03.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 1.232,91 | 1.303,90 | 1.360,16 | 1.402,01 | 1.446,09 | 1.463,98 | 1.620,00 | |
EBITDA1,2 | 125,54 | 125,33 | 80,23 | 101,16 | 105,65 | 105,88 | 117,00 | |
EBITDA-Margin3 | 10,18 | 9,61 | 5,90 | 7,22 | 7,31 | 7,23 | 7,22 | |
EBIT1,4 | 64,94 | 56,80 | 10,60 | 30,52 | 36,11 | 40,40 | 53,00 | |
EBIT-Margin5 | 5,27 | 4,36 | 0,78 | 2,18 | 2,50 | 2,76 | 3,27 | |
Net Profit (Loss)1 | 51,19 | 44,48 | 2,46 | 30,23 | 26,94 | 40,17 | 34,00 | |
Net-Margin6 | 4,15 | 3,41 | 0,18 | 2,16 | 1,86 | 2,74 | 2,10 | |
Cashflow1,7 | 49,50 | 47,30 | 113,30 | 97,50 | 41,30 | 109,00 | 85,00 | |
Earnings per share8 | 0,73 | 0,65 | 0,02 | 0,42 | 0,38 | 0,58 | 0,51 | |
Dividend per share8 | 0,29 | 0,00 | 0,00 | 0,00 | 0,15 | 0,00 | 0,00 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
Rhön-Klinikum | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
704230 | DE0007042301 | AG | 924,08 Mio € | 19.06.1991 | Halten | 9F2G86FM+GX |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
23,00 | 28,72 | 0,80 | 23,59 | 0,74 | 8,48 | 0,63 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,15 | 0,00 | 0,00 | 0,00% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
03.06.2025 | 08.05.2025 | 07.08.2025 | 07.11.2024 | 27.03.2025 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
+7,45% | +12,57% | +38,00% | +32,69% | +452,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.